Pressmeddelande

  • CEO Ulf Jungnelius to leave Isofol Medical on June 1, 2023

    GOTHENBURG, Sweden, November 28, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that Chief Executive Officer Dr.…

    by
  • Final data from the AGENT study confirms topline results

    GOTHENBURG, Sweden, November 25, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that analysis of the AGENT…

    by
  • Isofol appoints nomination committee ahead of the Annual General Meeting 2023

    GOTHENBURG, Sweden, November 3, 2022 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that…

    by
  • Invitation to presentation of Isofol’s report for the third quarter of 2022

    GOTHENBURG, Sweden, October 27, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), will publish the company’s results for…

    by
  • Isofol reports data from the AGENT study

    GOTHENBURG, Sweden, 7 september 2022 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL) today reported data from the AGENT study…

    by
  • Isofol provides update on the AGENT study

    GOTHENBURG, Sweden, August 31, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today announced that, having received access to…

    by
  • Invitation to presentation of Isofol´s report for the second quarter of 2022

    GOTHENBURG, Sweden, August 15, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) (“Isofol”), will publish the company’s results for…

    by
  • Isofol Announces Topline Results of Phase III AGENT Study – Did Not Meet Primary or Key Secondary Endpoints

    GOTHENBURG, Sweden, August 3, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced topline results that neither the…

    by
  • Isofol receives approval of biomarker analysis patent and intention-to-grant patent application for study dose regimen in Europe

    GOTHENBURG, Sweden, July 26, 2022 – Isofol Medical AB (http://isofol.se/en/) (publ) (Nasdaq Stockholm: ISOFOL), today announced the European approval for a…

    by
  • Isofol updates start time of live-streamed R&D event on June 20 to 14:00 CEST

    GOTHENBURG, Sweden, June 17, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that the company is postponing…

    by